A small biopharmaceutical company sought to develop a robust US forecast model for a rare disease therapy launching within the next year. The company required a structured approach to incorporate insights from ongoing market research, analog case studies, and stakeholder inputs to ensure the forecast was both comprehensive and actionable.
Arya Consulting teams collaborated closely with the business development, portfolio strategy and global cross-functional teams (Development, Market Access and Medical Affairs) to develop an early commercialization strategic plan for CAR cell therapy assets by:
Conducting working sessions with 8 separate functional teams, regional/affiliate representatives and CAR Cell Therapy subject matter experts to develop an initial draft of the CAR cell therapy roadmap, which includes key strategic activities, timing, risks and milestones
Facilitating primary research with select experts to gather additional insights, pressure-test assumptions and validate timings of select strategic activities
Synthesizing primary research findings and insights from working sessions to modify the early CAR cell therapy strategic plan as needed
Developing an executive presentation to provide an overview of insights uncovered around cell therapy proof of concept programs, competitive market assessment to early access programs
The Arya team worked closely with the commercial lead to design a US forecast model by:
Assessing analog case studies to inform product uptake estimates
Developing targeted criteria and weighting scale to ensure analogs are evaluated consistently and align with main characteristics of the rare disease produc
Identifying potential analogs from historical launches and evaluating each one against the criteria
Evaluating the scored analogs, focusing on those with the highest alignment to the rare disease product, and selecting a subset that provides a representative benchmark for uptake trends
Facilitating cross-functional discussions to align on core inputs, including payer access, patient assistance, patient dropout, and pricing
Analyzing market research outputs to inform core assumptions, including target patient population, provider preference share, and physician overstatement
Developing a comprehensive US forecast model based on market research findings and aligned assumptions, ensuring all inputs reflect real-world dynamics and strategic goals
Developing a comprehensive US forecast model based on market research findings and aligned assumptions, ensuring all inputs reflect real-world dynamics and strategic goals
Synthesizing findings into an actionable presentation for the core team, providing insights to support strategic decision-making
The Arya team supported successful implementation of the Value Clinic 2.0 concept by:
Designing the workshop structure, agenda, exercises, and presentation materials aligned with Value Clinic 2.0 objectives for virtual settings, integrating inputs from Value Clinic 1.0 and current asset resources
Presenting key market access trends, commercial insights and payer / HTA requirements to level set the cross-functional team (Market Access, Commercial, Development, Medical, HEOR, Regulatory)
Analyzing the asset’s TPP to align the team on its key value differentiators and how it addresses the target value proposition and uncover areas to further explore
Building a comprehensive SWOT to highlight the asset’s positive value attributes and catalogue unknowns / possible evidence gaps
Discussing and aligning on stakeholder beliefs on the asset value position from the perspectives of patients, physicians, payers, policymakers and regulators
Developing ‘message themes’ and review the strategic framework with identified value differentiators from these cross-functional workshops
The Arya team supported development of robust situational analyses for the six tumor types by:
Performing secondary research and distilling key insights
Creating a disease state overview including epidemiological characteristics, risk factors, disease staging and prognosis, and patient treatment flow
Assessing the market including number of patients by disease stage, incidence by market and age, and growth rate through / beyond anticipated launch; provided market sizing factors, drivers, and constraints
Outlining treatment options / clinical guidelines by region and physician prescribing trends
Developing a competitor assessment with current and pipeline therapies, including their mechanism of action, clinical data, positioning, commercial advantages / limitations
Outlining global payer landscape and access trends within oncology
Working closely with a cross-functional client team comprised of 11 functions, the Arya team supported indication prioritization by:
Constructing a comprehensive list of potential indications to be included in project scope by evaluating previous projects related to the asset as well as the company’s other molecules
Establishing an evaluation framework, including consideration of prior prioritization initiatives, and providing appropriate rationale for all criteria included
Creating a scoring and weighting methodology by incorporating accepted practices from existing prioritization initiatives and client input
Prioritizing indication opportunities with input from a cross-functional team whose membership aligned with the set evaluation criteria
Providing a list of key opportunities to consider pursuing based on scores as well as client team insights
Delivered an interactive and customizable US forecast model to test various market scenarios
Aligned on key market assumptions through stakeholder collaboration, ensuring a cohesive and data-driven approach
Created a detailed output presentation summarizing insights, enhancing cross-functional understanding and facilitating decision-making
Get expert analysis, industry trends, and exclusive updates delivered straight to your inbox. Stay ahead of the curve with valuable insights that drive success.
